SuperworthAbCellera Biologics EPS ABCL
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.54
- Latest quarter, Q2 FY26
- −$0.18
- Fiscal year 2025
- −$0.49
AbCellera Biologics' earnings per share was −$0.54 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.18.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.49 | n/a |
| FY2024 | −$0.56 | n/a |
| FY2023 | −$0.51 | −202% |
| FY2022 | $0.50 | +4% |
| FY2021 | $0.48 | +92% |
| FY2020 | $0.25 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.18 | n/a | −$0.54 | |
| Q1 FY26 | −$0.14 | n/a | −$0.48 | |
| Q4 FY25 | −$0.03 | n/a | −$0.49 | |
| Q3 FY25 | −$0.19 | n/a | −$0.58 | |
| Q2 FY25 | −$0.12 | n/a | −$0.56 | |
| Q1 FY25 | −$0.15 | n/a | −$0.57 | |
| Q4 FY24 | −$0.12 | n/a | −$0.56 | |
| Q3 FY24 | −$0.17 | n/a | −$0.60 | |
| Q2 FY24 | −$0.13 | n/a | −$0.53 | |
| Q1 FY24 | −$0.14 | n/a | −$0.51 | |
| Q4 FY23 | −$0.16 | n/a | −$0.51 | |
| Q3 FY23 | −$0.10 | −225% | −$0.45 |
Against its peers
Companies in Drug Manufacturers - General nearest AbCellera Biologics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ABCLAbCellera Biologics | −$0.54 | |
| OGNOrganon | $0.77 | −71% a year |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| NRIXNurix Therapeutics | $2.31 | |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| Peer median | $1.85 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on AbCellera Biologics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.